Retatrutide Wholesale
Triple Agonist Bulk Supply
The world’s most potent research peptide in active Phase 3 trials. Retatrutide (LY3437943) simultaneously activates GLP-1, GIP, and the glucagon receptor — a triple agonist profile no other wholesale peptide can match. HPLC-verified ≥98% purity, full COA every batch, 5mg to 30mg lyophilized vials.
What Is Retatrutide? The Triple GLP-1/GIP/Glucagon Agonist Explained
Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly as a triple receptor agonist, simultaneously targeting the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). It is the most advanced triple agonist in human clinical trials and the fastest-growing research peptide of 2026, with a +512% year-over-year increase in search volume and over 250,000 monthly searches for retatrutide wholesale and related terms.
The key differentiator from tirzepatide (dual GIP/GLP-1) and semaglutide (GLP-1 only) is retatrutide’s activation of the glucagon receptor. Glucagon receptor agonism directly increases energy expenditure and promotes hepatic fat oxidation — mechanisms not activated by dual or single incretin agonists. This triple receptor engagement has produced the highest body weight reduction data of any peptide class in published Phase 2 clinical trials.
For wholesale buyers, retatrutide is supplied as a research-grade lyophilized powder. HPLC-verified at ≥98% purity, every batch ships with a complete Certificate of Analysis including mass spectrometry identity confirmation, endotoxin testing (LAL method), and residual solvent panel. Competitor listings often call it “Reta (GLP-3)” — a term no one searches and a signal of thin product knowledge. The correct and searchable name is retatrutide.
Triple Receptor Mechanism
Retatrutide activates three distinct metabolic receptors: GLP-1R (appetite suppression, insulin secretion), GIPR (incretin amplification, lipid metabolism), and GCGR (energy expenditure, hepatic fat oxidation). No other peptide available for wholesale research activates all three pathways simultaneously.
Phase 2 Trial Data
The TRIUMPH Phase 2 trial (NEJM, 2023) demonstrated up to 24.2% body weight reduction at 48 weeks on the 12mg weekly dose — the highest published efficacy data of any injectable peptide in a Phase 2 human trial. Phase 3 trials (TRIUMPH-3 and TRIUMPH-4) are actively enrolling as of 2026.
Fastest-Growing Peptide 2026
Retatrutide search volume has grown +512% year-over-year entering 2026. With Phase 3 trial results expected in late 2026/early 2027, institutional and research demand for retatrutide wholesale is accelerating ahead of any potential FDA approval pathway.
Molecular Architecture
Retatrutide is a 36-amino-acid peptide (MW ~4,556 Da) with a C20 fatty diacid side chain enabling extended half-life for weekly dosing in clinical research protocols. Its synthesis complexity — three-receptor engagement encoded in a single peptide — demands rigorous COA verification from any wholesale supplier.
Retatrutide vs Tirzepatide vs Semaglutide — Triple vs Dual vs Single Agonist
Understanding the receptor profile differences between these three wholesale peptides is essential for research protocol selection. Retatrutide is the only compound that activates the glucagon receptor in addition to GLP-1R and GIPR — this is the defining pharmacological distinction.
The glucagon receptor (GCGR) component of retatrutide’s profile drives direct thermogenic and hepatic effects absent in both semaglutide and tirzepatide. For wholesale buyers stocking research protocols across multiple GLP-1 class compounds, retatrutide represents the highest-signal third option in the incretin agonist category.
Retatrutide Wholesale — Full Specifications
Every retatrutide vial meets or exceeds the following specifications. COA documentation available for every lot number prior to purchase.
Chemical & Molecular Data
| Peptide Name | Retatrutide (LY3437943) |
| Sequence Length | 36 amino acids |
| Molecular Weight | ~4,556 Da |
| CAS Number | 2381272-91-7 |
| Target Receptors | GLP-1R, GIPR, GCGR (triple) |
| Side Chain | C20 fatty diacid (extended t½) |
| Physical Form | Lyophilized powder |
| Solubility | Bacteriostatic water, sterile water |
Quality & Purity Standards
| HPLC Purity | ≥98% (batch tested) |
| Identity | Mass spectrometry confirmed |
| Endotoxin | <1 EU/mg (LAL method) |
| Sterility | Sterile-filtered, aseptic fill |
| Water Content | <5% (Karl Fischer) |
| Residual Solvents | ICH Q3C compliant |
| Storage (lyophilized) | -20°C · up to 24 months |
| Post-reconstitution | 4°C · use within 28 days |
Retatrutide Wholesale Price — All Sizes 2026
Pricing rewards volume. Larger vials deliver lower cost per milligram. All prices include full COA documentation. Additional discounts at 25+ and 50+ unit orders.
| Size | Price Per Vial | Cost Per mg | Min. Order | 10+ Unit Price | Availability |
|---|---|---|---|---|---|
| Retatrutide 5mg | $93 | $18.60 / mg | 5 vials | $81 / vial | ✓ In Stock |
| Retatrutide 10mgBEST VALUE | $160 | $16.00 / mg | 5 vials | $142 / vial | ✓ In Stock |
| Retatrutide 20mg | $285 | $14.25 / mg | 5 vials | $255 / vial | ✓ In Stock |
| Retatrutide 30mg | $390 | $13.00 / mg | 5 vials | $350 / vial | ✓ In Stock |
How Retatrutide Works — Triple Agonism Explained
Retatrutide’s pharmacological uniqueness comes from its balanced engagement of three distinct metabolic receptors. Each receptor pathway contributes a distinct physiological effect, and their simultaneous activation produces a combined profile that exceeds what dual or single agonists can achieve.
GLP-1 Receptor Agonism
At the GLP-1 receptor, retatrutide drives insulin secretion in a glucose-dependent manner, reduces gastric emptying rate, and activates anorexigenic signaling in the hypothalamus. This is the same receptor targeted by semaglutide and is well-established in the published research literature as a primary metabolic regulator.
GIP Receptor Agonism
At the GIP receptor (GIPR), retatrutide mimics the action of native GIP — the dominant incretin hormone in metabolically healthy individuals. GIPR activation amplifies insulin secretion, influences lipid metabolism and adipose tissue signaling, and complements GLP-1R activity in ways that dual agonism research has extensively documented.
Glucagon Receptor Agonism — The Critical Third
The glucagon receptor (GCGR) is the defining differentiator. GCGR agonism directly increases hepatic glucose production, promotes hepatic fat oxidation (relevant to MAFLD/NASH research), and increases resting energy expenditure through thermogenic signaling. This component is absent in semaglutide and tirzepatide, and is the pharmacological basis for retatrutide’s Phase 2 efficacy data.
Coordinated Triple Signaling
The simultaneous activation of GLP-1R, GIPR, and GCGR creates a coordinated metabolic signaling environment that individual or dual receptor approaches cannot replicate. Research has examined receptor crosstalk, signal amplification, and synergistic pathway interactions as areas of active investigation — making retatrutide a uniquely valuable compound for multi-receptor metabolic research protocols.
Retatrutide in Clinical Research — TRIUMPH Trial Program
Retatrutide is one of the most actively studied peptides in current clinical research. The following summarizes key published findings and ongoing research programs. All references pertain to published scientific studies, not clinical claims for the research-grade wholesale product.
TRIUMPH Phase 2 — The Landmark Publication
The Phase 2 TRIUMPH trial (2023) evaluated retatrutide at doses of 1mg, 2mg, 4mg, 8mg, and 12mg weekly over 48 weeks in participants without type 2 diabetes. The 12mg dose cohort achieved a mean body weight reduction of 24.2% — the highest published efficacy figure for any injectable peptide in a Phase 2 human trial, surpassing both tirzepatide (~22.5% in SURMOUNT-1) and semaglutide (~15% in STEP-1).
Published in New England Journal of Medicine, 2023
TRIUMPH-3 & TRIUMPH-4 — Active Phase 3 Trials (2026)
As of 2026, Eli Lilly’s TRIUMPH-3 and TRIUMPH-4 Phase 3 trials are actively enrolling. TRIUMPH-3 evaluates retatrutide in adults with obesity, while TRIUMPH-4 evaluates it in participants with type 2 diabetes. Phase 3 results are expected in late 2026 or 2027, with any FDA approval pathway contingent on those outcomes. This makes 2026 a pivotal year for retatrutide research interest and wholesale demand.
Active registrations at ClinicalTrials.gov
Hepatic & MAFLD Research Applications
The glucagon receptor component of retatrutide’s profile has generated significant research interest in metabolic-associated fatty liver disease (MAFLD) and non-alcoholic steatohepatitis (NASH). GCGR agonism drives hepatic fat oxidation and reduces hepatic lipid accumulation — pathways directly relevant to liver disease models. Retatrutide is the only wholesale-available peptide with intrinsic GCGR activity, making it uniquely positioned for hepatic metabolic research protocols.
Multiple publications in Journal of Hepatology, Hepatology, 2023–2025
Cardiovascular & Cardiometabolic Research
Retatrutide’s triple receptor profile has attracted early research interest in cardiovascular outcomes, including effects on lipid profiles, blood pressure, and cardiac metabolic efficiency. The combination of GLP-1R (established cardiovascular benefit in peer-reviewed literature), GIPR, and GCGR creates a novel cardiometabolic research target with no direct comparator in the existing wholesale peptide catalog.
Emerging publications, 2024–2025
Retatrutide Wholesale Quality Standards
Retatrutide synthesis is demanding. Its three-receptor engagement requires precise molecular construction — errors in the fatty acid side chain or peptide sequence can produce a compound that appears structurally similar but is pharmacologically inert or contaminated. Verifiable documentation is not optional.
Full COA Per Lot
Every batch ships with a COA. Lot numbers match vials. Available pre-purchase on request.
HPLC + Mass Spec
Purity ≥98% by HPLC. MW ~4,556 Da confirmed by mass spectrometry — not assumed.
Endotoxin Tested
LAL endotoxin testing <1 EU/mg. Sterility confirmed by aseptic fill and sterile filtration.
Cold-Chain Shipping
Lyophilized vials ship cold-chain. Stable at -20°C up to 24 months.
Sequence Verified
36-amino-acid sequence and C20 fatty diacid side chain confirmed per lot.
48h Fulfillment
In-stock orders ship within 48 business hours with tracking and cold-chain manifest.
Who Buys Retatrutide Wholesale
Retatrutide wholesale supply is purpose-built for professional, licensed, and institutional buyers. Not available to the general public.
Compounding Pharmacies
503A and 503B pharmacies building retatrutide protocols ahead of anticipated FDA Phase 3 data and approval pathway decisions.
Research Institutions
Universities, CROs, and biotech labs running preclinical triple agonist, metabolic, hepatic, or cardiovascular research protocols.
Licensed Clinics
Weight management and metabolic health clinics operating under physician oversight requiring research-grade triple agonist supply.
Pharmaceutical CDMOs
Contract development organizations requiring retatrutide as a reference standard or formulation development compound.
Peptide Distributors
B2B wholesale distributors supplying downstream licensed research buyers as Phase 3 demand accelerates through 2026.
Longevity & Medical Practices
Anti-aging and regenerative medicine practices tracking retatrutide ahead of any potential FDA approval and compounding availability.
Retatrutide Wholesale — Frequently Asked Questions
Research Use Only: All products listed on this page, including retatrutide, are sold strictly for in vitro research, laboratory, and compounding use only. These products are not intended for human or veterinary use, consumption, injection, or any therapeutic application. They are not FDA-approved drugs or dietary supplements. Retatrutide is currently in Phase 3 clinical trials and has not received FDA approval as of 2026. No claims are made regarding safety, efficacy, or therapeutic benefit in humans or animals. Buyers are solely responsible for compliance with all applicable federal, state, and local laws governing purchase, possession, and use of research chemicals and peptides. By purchasing, you confirm you are a licensed researcher, compounding pharmacist, or qualified institutional buyer acting within the scope of a legitimate research or compounding program.
Reviews
There are no reviews yet.